- Home
- FNLC vs SLP Comparison
FNLC vs SLP Comparison
Compare FNLC & SLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FNLC | SLP |
|---|---|---|
| Founded | 1864 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | EDP Services |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.7M | 322.4M |
| IPO Year | 1999 | 1997 |
Fundamental Metrics
Financial Performance| Metric | FNLC | SLP |
|---|---|---|
| Price | $25.91 | $18.16 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $27.25 |
| AVG Volume (30 Days) | 25.5K | ★ 247.1K |
| Earning Date | 01-21-2026 | 01-08-2026 |
| Dividend Yield | ★ 5.71% | N/A |
| EPS Growth | ★ 18.07 | N/A |
| EPS | ★ 2.81 | N/A |
| Revenue | ★ $88,119,000.00 | $79,179,000.00 |
| Revenue This Year | N/A | $2.42 |
| Revenue Next Year | N/A | $7.05 |
| P/E Ratio | $9.22 | ★ N/A |
| Revenue Growth | 12.70 | ★ 13.09 |
| 52 Week Low | $22.11 | $12.39 |
| 52 Week High | $28.60 | $37.67 |
Technical Indicators
Market Signals| Indicator | FNLC | SLP |
|---|---|---|
| Relative Strength Index (RSI) | 50.55 | 45.20 |
| Support Level | $26.16 | $17.73 |
| Resistance Level | $27.93 | $19.78 |
| Average True Range (ATR) | 0.58 | 0.73 |
| MACD | -0.15 | -0.10 |
| Stochastic Oscillator | 31.37 | 20.49 |
Price Performance
Historical ComparisonAbout FNLC First Bancorp Inc (ME)
First Bancorp Inc is a Damariscotta-based bank holding company providing a range of retail and commercial banking services including deposit accounts and consumer, commercial and mortgage loans. The company provides investment management and private banking services through an operating division of the bank. Its revenues are generally derived from dividends paid to the company by the bank.
About SLP Simulations Plus Inc.
Simulations Plus Inc is engaged in the software industry. It includes two segments. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.